Voltage-gated sodium channel alpha subunit (Nav alpha) (Nav alpha)

Voltage-gated sodium channel alpha subunits are large, pore-forming transmembrane proteins essential for the initiation and rapid propagation of action potentials in excitable cells, including neurons, cardiomyocytes, and skeletal muscle fibers [1, 2]. The human genome contains nine distinct alpha subunit genes (SCN1A through SCN11A), which encode the isoforms Nav1.1 to Nav1.9 [2, 5]. These subunits are critical for physiological processes such as signal transduction in the central nervous system, cardiac rhythm maintenance, and peripheral pain signaling [3, 6]. Mutations in these channels, known as channelopathies, are associated with a wide range of disorders, including Dravet syndrome (SCN1A), Brugada syndrome (SCN5A), and various inherited pain syndromes (SCN9A) [4, 6]. Pharmacologically, these subunits are the primary targets for local anesthetics, antiarrhythmics, and anticonvulsants, which generally act by blocking the ion-conducting pore or modulating channel gating [7, 8]. Modern therapeutic strategies aim to develop isoform-selective modulators to improve efficacy and reduce off-target effects, such as avoiding cardiac toxicity when treating neurological conditions [2, 7].

Other names

SCN1ASCN2ASCN3ASCN4ASCN5ASCN8ASCN9ASCN10ASCN11ANav1.1Nav1.2Nav1.3Nav1.4Nav1.5Nav1.6Nav1.7Nav1.8Nav1.9Sodium channel protein type 1 subunit alphaSodium channel protein type 2 subunit alphaSodium channel protein type 5 subunit alpha

Voltage-dependent blockade of the sodium channel pore, typically favoring the inactivated state, to inhibit sodium ion influx and reduce cellular excitability [1, 7, 8].